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Abstract
With 1.6 million casualties annually and 2 billion people being infected, tuberculosis is still one of the most pressing
healthcare challenges. Here we report on the new computational docking algorithm FRIGATE which unites continuous local
optimization techniques (conjugate gradient method) with an inherently discrete computational approach in forcefield
computation, resulting in equal or better scoring accuracies than several benchmark docking programs. By utilizing FRIGATE
for a virtual screen of the ZINC library against the Mycobacterium tuberculosis (Mtb) enzyme antigen 85C, we identified novel
small molecule inhibitors of multiple drug-resistant Mtb, which bind in vitro to the catalytic site of antigen 85C.
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Introduction
All protein-ligand docking programs used for high throughput
virtual screening use scoring functions for evaluating the relative
positions of ligands and macromolecules [1,2]. Mathematical
optimization techniques are applied to find the best scoring
position of the ligand in the macromolecule. With the additional
need to allow ligand flexibility, this search for the best ligand
position corresponds to a mathematical optimization problem of
high dimensional space: the 3D position of the rigid small
molecule can be described by 3 real numbers describing one atom
of the small molecule plus 3 real numbers describing the Euler-
angles. Every rotatable bond adds one additional dimension.
Therefore a small molecule with 8 rotatable bonds needs to be
optimized in the 3+3+8=14-dimensional real space. Computa-
tionally optimizing complex energy-like scoring functions of small
molecule – macromolecule pairs in 14-dimensional space becomes
a formidable task. In this work we compare our solution, the
FRIGATE docking program, with 8 benchmark docking pro-
grams and demonstrate that FRIGATE yields promising small
molecule ligands for the Mycobacterium tuberculosis (Mtb) enzyme
antigen 85C.
Tuberculosis (TB) is the second highest cause of death from
infectious disease, killing 1.6 million people annually. An estimated
one third of the world population is latently infected with Mtb, the
causative agent of TB [3]. While vaccination is largely ineffective
in preventing adult pulmonary disease, the WHO recommended
multi-drug treatment comprises 2 months of directly observed
therapy with isoniazid, rifampicin, pyrazinamide and ethambutol
followed by a minimum of 4 months of isoniazid and rifampicin.
The complexity and duration of this treatment leads to poor
disease control and the emergence of multi drug-resistant (MDR)
and extensive drug-resistant (XDR) TB. Present second-line
antibiotics for the treatment of resistant TB are inherently
inadequate either due to limited efficacy or associated toxicities,
indicating a high medical need for more field-effective anti-
tuberculars [4].
The discovery of efficacious anti-tuberculars is particularly
demanding due to the mycolic acid shield of the mycobacterial cell
wall, which is essential for both viability and virulence of Mtb and
targeted by the first-line anti-tuberculars isoniazid and ethambutol
[5]. Cell wall mycolic acids are b-branched, c-hydroxy fatty acids
of 70 to 90 carbon atoms occurring as esters of arabinogalactan-
peptidoglycan (mAGP) and trehalose, an a-1,19-glucose disaccha-
ride [6]. The transfer of mycolic acids from trehalose mono-
mycolate (TMM) to trehalose dimycolate (TDM, cord factor) is
catalyzed by the transferases antigen 85A, B and C (Ag85A, B, C)
[7], which possess an almost invariant active site composed of a
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site and an extended hydrophobic channel thought to harbor the
mycolic acid chain [8,9].
Genetic knock-out of Ag85C in Mtb suppresses the amount of
cell-wall linked mycolic acids by 40%, and knock-out of the Ag85A
gene results in loss of Mtb replication in human and mouse
macrophages [10]. RNA interference knock-down of Ag85A, B
and C slows down Mtb growth in broth by 2 log units [11].
Covalent small molecule blockage with 6-azido-69-deoxytrehalose
weakly inhibits the growth of Mycobacterium aurum with a minimum
inhibitory concentration (MIC) of 200 mg/mL [7]. Immunological
analysis of TB infected patients shows that Ag85A, B, C and D
belong to the major Mtb antigens, indicating that these proteins are
accessible to immune cells and probably small molecules.
Considering these data and the therapeutic success of other cell
wall biosynthesis inhibitors, we chose Ag85C as a promising
surrogate target for the discovery of new anti-tuberculars by
computational screening.
Here we report the identification of the novel binder N-[3-(1H-
imidazol-1-yl)propyl]-1-benzyl-9-methyl-4-oxo-1,4-dihydropyr-
ido[1,2-a]pyrrolo[2,3-d]pyrimidine-2-carboxamide (1) to the cata-
lytic site of Ag85C by the novel FRIGATE virtual screening
algorithm. The binding site of 1 is experimentally confirmed by
protein-detected NMR spectroscopy. Moreover we demonstrate
that 1 inhibits the growth of Msmeg and MDR-Mtb in liquid broth
at MICs of 50 and 20 mg/mL, respectively.
Results and Discussion
FRIGATE facilitates local optimization of ligand poses
Conceptually virtual screening is one of the fastest and most
resource sparing approaches for identifying drug-like ligands to
protein targets of known 3D structure. The scoring functions of
virtual screening algorithms are frequently related to the molecular
energies or potential functions. The exact description of the force
fields in each geometric point around a target molecule is not
possible, since there are infinitely many points. An approximation
of the force field with a finite number of points, arranged in a
cubic grid, is the usual solution, as embedded in the program
AutoDock [12]. However, this discretization of the force field
exacerbates the local optimization (energy minimization) because
derivation and gradient methods need continuous, differentiable
potential functions.
The new FRIGATE docking software of Uratim Ltd. [13]
applies a novel hybrid approach: it discretizes the energy potentials
around a protein molecule in order to be computationally feasible,
and then uses a continuous local optimization technique, namely
the scaled conjugate gradient (SCG) algorithm [14], for the twice
continuously differentiable B-spline interpolation of the force field,
based on discretized data points. The energy-based algorithm of
FRIGATE computes the total free energy change, DG, from the
sum of intermolecular and intramolecular terms as follows:
DG~DGinterzDGintra
The intermolecular energy terms are given by the equation:
DGinter~CvdWDGvdWzChbDGhbzCelecDGeleczCsolDGsol
where on the right hand side of the equation sums the terms for
van der Waals energy, hydrogen-bonding energy, electrostatic
energy and solvation energy, respectively. Each term is weighted
with a coefficient, determined from experimental binding
constants using linear regression analysis, according to reference
[12]. The intramolecular energy term, DGintra, describes the
intramolecular van der Waals interactions and the torsional energy
terms in the docked ligand.
The FRIGATE program consists of the following parts
(a) Protein preparation. The three-dimensional structures
of the proteins are taken from a PDB formatted file. The
coordinates of the missing H atoms are computed, and partial
charges are assigned to atoms, in order to compute later the
electrostatic potential, the fragmental volume and the solvation
energy terms. Directional parameters for computing hydrogen
bonding energy terms for (i) oxygen atoms in the protein and (ii) H
atoms in the protein are also calculated. The parameters gained
are stored in the Receptor Specification File (RSF) of the protein.
(b) Grid calculation. Similarly to the AUTODOCK
program [12], FRIGATE pre-computes the energy function
around the protein molecule in the points of a three dimensional
rectangular grid. Each possible ligand atom (i.e., polar hydrogen,
aliphatic carbon, aromatic carbon, nitrogen, oxygen, phosphorus,
sulfur, fluorine, chlorine, bromine, iodine, non-polar hydrogen) is
placed in each possible grid point, and the energy affecting that
atom is calculated and stored in a file called gridmap. The closest
grid points are 0.375 A ˚ apart which is roughly a quarter of a
carbon-carbon bond length. Pre-computing and storing of the
gridmap facilitates the fast computation of the energies of millions
of flexible ligand conformations relative to the static protein
molecule.
(c) Spline approximation. The pre-computed energy values
of the discrete grid facilitatethe fast computationof energyterms for
ligand atoms that are exactly positioned in the grid points. Energies
affecting ligand atoms between discrete grid points are computed
from an approximation of the energies of the surrounding grid
points. Unlike other programs, FRIGATE applies a twice
continuously differentiable B-spline approximation function for
this goal, therefore the energy function affecting the ligand atoms
can be minimized locally with conjugate gradient methods [14,17].
(d) Local minimization. The Scaled Conjugate Gradient
(SCG) algorithm is applied for local minimization. It is detailed in
the Methods section in Text S1.
(e) Global minimization. The Competitive MultiStart
algorithm is used for global optimization. It is detailed in the
Methods section in Text S1.
Parameterization of FRIGATE
We optimized the SCG algorithm of FRIGATE against the
thorough dataset of 100 high-resolution protein-ligand crystal
structures utilized previously for benchmarking the eight popular
docking programs DOCK, FLEXX, FRED, GLIDE, GOLD,
SLIDE, SURFLEX and QXP [15]. These 100 public crystal
structures comprises 97 diverse drug-like ligands, as evidenced by
ligand molecular weights between 88 and 730 Da, total polar
surface areas between 20 and 210 A ˚ 2 [16]. For our FRIGATE
training dataset we generated 100 random ligand conformations
for each of the 100 protein-ligand complexes. We observed that
the SCG algorithm performs much slower when the resulting
local optimum was in the positive region of the function.
Therefore a global search was run to select the 100 starting
ligand conformations that yield the lowest energy function values
for each protein. This resulted in one biased training dataset of
100 * 100 lowest energy ligand starting conformations and a
second unbiased dataset of another 100 * 100 ligand starting
conformations.
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S1) because there was no clear indication for its optimal value in
the original paper [17]. We measured the average number of
function and gradient evaluations the algorithm used in a local
optimization run over the training sets described above, varying s
between 10
213 and 10
25 at the two convergence criteria
eg=10
210 and eg=10
25. The results clearly indicate that the
optimal value for s is around 10
29 (Fig. S1), which is used for all
subsequent tests. However, when the convergence criterion is not
very strict, the algorithm is quite insensitive to the value of s.
Next the competitive multistart (CMS) algorithm (Text S1) for
global optimization was tested. We used the same training set of
100 ligand-protein complexes as before, but with randomized
ligand conformations. Since the global energy function optimum
of a ligand-protein complex is a priori unknown, we used the
energy of the ligand protein crystal structure as the best available
approximation. Further energy minimization by the local SCG
algorithm with the strict convergence criterion eg=10
215 yielded
our best guess for the reference global energy optimum.
The CMS algorithm was run using the SCG method as the local
optimization subroutine with s=10
29, eg=10
28 and 0.5*10
6,
1*10
6, 1.5*10
6 and 2*10
6 function evaluations. Some ligand-
protein complexes produced global energy minima below the
reference optimum. In these cases our new estimate for the
reference global optimum became this lower energy record.
Comparing the results of the CMS global optimization to this
reference optimum shows that the energies of the locally optimized
ligand conformations are in about 80% of all test cases within
0.5 kcal/mol of the reference optimum (Fig. 1A). However, for
ligands with 15 or more degrees of freedom the global search
algorithm quickly drops in reliability (Fig. 1B), thereby limiting the
application of FRIGATE to ligands with less than 15 to 18 degrees
of freedom.
Comparing FRIGATE to benchmark docking programs
Two pivotal quality parameters for computational screening
and docking programs are docking accuracy and scoring accuracy.
Utilizing the aforementioned dataset of 100 ligand-protein crystal
structures [15], we firstly energy minimized the crystallographic
ligand conformer in vacuum in order to mimic virtual screening
applications where the bound ligand conformer is unknown.
Secondly we ran FRIGATE with 0.5*10
6, 1*10
6, 1.5*10
6 and
2*10
6 energy function evaluations for each ligand-protein complex
and retained the 30 top scoring ligand poses for each complex.
Next we counted all retained ligand poses that are found within a
certain rmsd distance from the experimental X-ray pose [16].
Plotting this number of poses as a percentage of all complexes
against a meaningful rmsd distance scale of 0 to 2 A ˚ gives a
graphical representation of the docking accuracy (Fig. 2A). When
2*10
6 energy function evaluations are calculated FRIGATE poses
68% of the top 30 scoring ligands within 2 A ˚ of the crystallized
ligand, which is approximately as good as the mean docking
accuracy of the eight benchmark programs assessed in a previous
study [15].
The scoring accuracy plot (Fig. 2B) shows the percentage of all
100 ligand-protein complexes where the top scoring pose lies
within a certain rsmd distance from the experimental pose. Again
with 2*10
6 energy function evaluations FRIGATE puts the top
scoring pose in 52% of all complexes within 2 A ˚ rsmd distance of
the crystallized ligand. This scoring accuracy compares very well
with the better half of the eight benchmark programs [15]. Taking
into account that FRIGATE utilizes the unbiased energy
minimized ligand conformer, suggests that the FRIGATE docks
and scores ligands, whose bound conformation is unknown,
comparatively accurately.
We hypothesize that the superior performance of FRIGATE
stems from its two-step approach: firstly, FRIGATE mimics the
random move of a ligand through the stochastic approach of CMS
global optimization. Secondly, FRIGATE fine-tunes the global
minimum by following the robust SCG energy optimization path
of molecular dynamics. On average FRIGATE docks one ligand
in 10–20 sec on a 64 bit Celeron Intel processor, providing
sufficient speed for virtual screens of .1 Mio. ligands.
FRIGATE identifies novel ligands to Ag85c
In this study we test FRIGATE on the potential anti-TB target
protein Ag85C of Mtb, which appears well suited due to its deep
TMM binding trough and the availability of two co-crystal
structures with the substrate mimetics OTG and trehalose in the
catalytic site. In addition FRIGATE covers potential allosteric
ligand binding sites, thereby enabling the discovery of allosteric
modulators which frequently go undetected in experimental or
active site pharmacophore-based computational screens. As the
ligand database for FRIGATE we used the 2,066,536 drug-like
and Rule-of-5 compliant compounds of the ZINC library, which
exclusively contains commercially available compounds for
Figure 1. Performance and limitations of the global optimization algorithm CMS. (A) The number of test cases that were successfully
optimized within a certain energy threshold from the reference value. On the left figure the reference value was the current estimate for the global
optimum, and on the right it was the energy of the local optimized X-ray conformation of the ligand. (B) For all training set ligands with 6–14 degrees
of freedom, the CMS algorithm finds an energy minimum within +0.5 kcal/mol of the crystallographic complex (DEXray). For ligands with 15 or more
degrees of freedom, the CMS minimization performance becomes worse than DEXray+0.5 kcal/mol for an increasing number of complexes.
doi:10.1371/journal.pone.0028428.g001
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generated with the program Omega (OpenEye), and the partial
charges were calculated with the semi-empirical quantum
mechanical program AMSOL [19].
A second solubility-filtered ligand database was generated by
removing molecules from the abovementioned ZINC set that are
unlikely to be soluble in water. We kept only molecules with ClogP
values of less than 3 or polar desolvation energies of less than
230 kJ/mol, resulting in a database of 1,035,013 molecules.
The FRIGATE screen of the 2,066,536-molecule unfiltered
library was completed within less than 320 hours on a cluster of 48
processors, using the coordinates of the apo Ag85C crystal
structure [20]. Hit compounds were rank ordered according to
their computed docking energies by the FRIGATE program. Of
the 100 top scoring VS hits, 96 compounds were docked into the
deep catalytic site of Ag85C and merely 4 into a second shallow
surface site between residues D44 and Y172. The clear preference
for the catalytic site demonstrates that FRIGATE places hits into
the most druggable site. However the docking scores of the
4 second site hits do not rank them to the bottom of top 100 list as
estimated from the lower druggability of this site, but rather
throughout the list at positions 11, 43, 51 and 86. Consequently
FRIGATE does identify surface binders, which is useful for
discovery programs on non-catalytic targets and allosteric sites, but
its docking energies do not unambiguously direct one to the most
druggable site.
Experimental hit validation by NMR
The 60 top ranking FRIGATE hits from the solubility filtered
library were manually checked for chemical attractiveness and
commercial availability at reasonable cost, resulting in the
acquisition of 23 compounds. Since less polar compounds may
favorably interact with the sizable hydrophobic trough in the
catalytic site of Ag85C and solubility filtering often suffers from
false-positives, we additionally assessed the 60 top ranking VS hits
from the unfiltered library. This led to another 8 compounds that
were commercially available and chemically attractive (Table S1).
The total of 31 compounds were tested for direct binding to
Ag85C by NMR and for mycobacterial growth inhibition against
Mycobacterium smegmatis (Msmeg). In the
15N-HSQC-NMR binding
assay, compounds 1 and 2 (Fig. 3A+B) show strong chemical shift
perturbations (CSPs) of the
1H-
15N backbone amide signals of
Ag85C (Fig. 4A), compound 3 (Fig. 3C) and two further
compounds show weak CSPs, one compound shows protein
Figure 2. Docking (top) and scoring (bottom) accuracy of FRIGATE compared with benchmark programs [15]. (A) FRIGATE docks ,68%
(horizontal line) of the 30 top scoring ligand poses within 2 A ˚ of the crystallographic pose, which matches the average performance of the
benchmark programs. (B) FRIGATE scores ,52% of the top scoring ligand poses within 2 A ˚ of the crystallographic pose, which exceeds the
performance of FRED1.1 (arrow) by ,23%.
doi:10.1371/journal.pone.0028428.g002
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(Table S1). CSPs are local, residue-based sensors for ligand –
protein interactions or ligand-induced alterations in local protein
conformation, and give a fingerprint of where the ligand binds to
the protein [21]. We categorized the CSPs of this single
concentration assay into ‘‘strong’’, ‘‘weak’’ and ‘‘inactive’’ in
comparison with two positive control ligands: the TMM mimetic
n-octyl-thioglucoside (OTG), whose binding to the catalytic site of
Ag85C is defined by a co-crystal structure [9], and the chemically
unrelated fragment 2-aminocyclohepta[b]thiophene-3-carbonitrile
(5) (Fig. S5), which was identified by experimental screening
against a diverse fragment library [22].
FRIGATE docking site confirms in NMR assay
Furthermore the CSPs were utilized to differentiate between
ligand binding to the catalytic site and other sites of Ag85C.
Comparing the CSPs between 1 and OTG shows that 20 out of a
total of 31 CSPs correlate, as defined by being larger than the
CSPs of 15 randomly selected reference peaks, which reflect the
random variation of the assay (Fig. S2; Fig. S4A). Similarly, 21 of
the same total of 31 CSPs correlate between 1 and 5 (Fig. S3; Fig.
S4B). These data indicate that 1 binds to the same site as OTG or
a directly adjacent sub-site in the catalytic cleft, which is in
agreement with the docking model of 1 (Fig. 3B). A small number
of divergent CSPs is within expectation because 1 and OTG as
well as 1 and 5 fill different segments of the catalytic pocket and
locally place variant ligand atoms in the vicinity of the protein
15NH groups.
Applying the same CSP correlation analysis to 2 yields 27 CSPs
out of the total 31 CSPs that correlate between 2 and OTG (Fig.
S4C), indicating binding the catalytic site, which again corrobo-
rates the docking model of 2 (Fig. 3B). The three weak binders
merely show a fraction of the CSPs observed for OTG and 5. Due
to this lack of data points, binding site information could not be
Figure 3. FRIGATE docking models of confirmed hits in the catalytic site of Ag85C. (A) 1 (C atoms dark green) superimposed on the co-
crystal structure of OTG (grey) bound to Ag85C [9] using the protein coordinates for the overlay. H bonds between OTG and Ag85C are shown as
dashed lines with distances in A ˚, including the catalytic oxyanion (Oc) of S124. The semi-transparent surface of Ag85C is color coded from polar (blue)
to hydrophobic (brown). (B) Superimposition of 2 (purple) (C) Superimposition of 3 (dark brown) (D) Superimposition of 1 to 3 onto OTG
highlighting the differential pocket coverage. Ligand color-coding identical to (A)–(C).
doi:10.1371/journal.pone.0028428.g003
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out of 31 FRIGATE hits confirmed in the NMR binding assay,
yielding a hit confirmation rate of 16%, which is within range of
the 1 to 20% hit rates of published target-based virtual screening
campaigns by other software programs [2,23]. The two most
active hits bind to the catalytic site of Ag85C, as predicted by
FRIGATE and expected from the superior druggability of this site.
Antibacterial activity testing
Learning from the rich literature of potent in vitro enzyme
inhibitors that were discarded due to the lack of antibacterial
activity [24], we assayed the 31 selected FRIGATE hits for
antibacterial activity prior to in vitro follow-up work. We utilized
the less pathogenic and faster growing Mtb model organism Msmeg
for primary growth inhibition testing. Of the total 31 FRIGATE
hits, 1 shows the strongest anti-mycobacterial activity with a MIC
value of 50 mg/mL or less (Fig. 5). Two further compounds 3 and
4 showed MIC values of 100 mg/mL, whereas the remaining 28
FRIGATE hits did not inhibit the growth of Msmeg at compound
concentrations between 50 and 200 mg/mL (Table S1). Hence 1
exhibits the highest activity in both the Ag85C binding assay and
the antibacterial Msmeg assay, while 3 is substantially less active in
these assays and 2 and 4 lack either anti-mycobacterial or Ag85C
Figure 4. NMR binding assay of 1. (a) The
15N-HSQC spectra of Ag85C in the presence of 50 mM (purple), 100 mM (green) and 200 mM (red) 1
show mono-directional (arrows) CSPs for exemplary residues (numbered, eg 42) as compared with apo-Ag85C (blue). Twelve randomly selected
reference residues (labeled r1–r12) remain unchanged. (b) Plotting the CSPs vs. the concentration of 1 allows one to fit a binding curve with an
average Kd value of 177 mM. CSP numbering identical to (a).
doi:10.1371/journal.pone.0028428.g004
Figure 5. Msmeg growth inhibition assay of 1 to 3. Addition of 50
and 100 mg/mL of 1 and 3, respectively, blocks the growth of Msmeg
beyond the level of visible detection, whereas Msmeg grows in the
presence of 50–200 mg/mL of 2. The reference antibiotic ampicillin
(Amp) inhibits Msmeg growth at 16 mg/mL as published previously [37].
Growth medium with (labeled ‘untreated’) and without bacteria
inoculum (labeled ‘no bacteria’) is colored black and pale yellow,
respectively.
doi:10.1371/journal.pone.0028428.g005
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but did not show binding to Ag85C in the
15N-HSQC spectrum, it
may inhibit Msmeg growth by a mechanism independent of
Ag85C.
On the basis of this data, we prioritized 1 for follow-up assays.
By 15N-HSQC-NMR titration experiments we determined a Kd
value of 177 mM for the in vitro binding of 1 to Ag85C (Fig. 4b).
Next we tested 1 against the MDR-Mtb strain 2745/09 in the
radiometric BACTEC 460 assay in liquid broth [25]. 1 stopped
the growth of this MDR-Mtb strain with a MIC of 20 mg/mL,
which is in good agreement with its MIC against Msmeg of
,=50mg/mL. The robust inhibitory effect on MDR-Mtb
demonstrates that 1 acts through a mode-of-action (MOA)
different from isoniazid and rifampicin, which define MDR-Mtb
strains and block mycolyl synthesis via enoyl-ACP reductase and
DNA-dependent RNA polymerase, respectively [26,27]. Testing 1
for bacteriotoxicity yielded no bactericidal activity against MDR-
Mtb up to a concentration of 80 mg/mL, which is not unexpected
at this low level of potency. In summary 1 blocks the growth of
Msmeg and MDR-Mtb with similar potency and shows potential for
combating the surge of MDR-Mtb infections.
Confirmed ligands show diverse pocket fill
The FRIGATE docking models of the experimentally validated
hits 1, 2 and 3 reveal that they converge in occupying most of the
central pocket as defined by OTG co-crystallized with Ag85C
(Fig. 3A–C). However, at both termini of the pocket they diverge
in the level of occupancy. 1 fills the hydrophobic sub-pocket more
thoroughly than 2 and 3, and penetrates deeper into this sub-
pocket than OTG (Fig. 3D), even though the carbonyl on the
tricycle of 1 may not be the most favorable functionality for this
lipophilic protein site lacking H bond donor counter-parts. In the
hydrophilic sub-pocket, 1 occupies a similar space as OTG, where
it mediates an H bond between its imidazole p electron cloud and
the NHe of W262 according to our model. OTG also forms an H
bond with W262.NHe through the O atom of its 49 hydroxy
group.
2 shows the least hydrophobic sub-pocket coverage, but
possesses more atoms interacting with the central and hydrophilic
sub-pockets. Its highly solvated carboxylate and amino moieties
stretch away from the protein into solvent (Fig. 3D), which may
favorably orient 2 for binding. In contrast to 1 and 3, 2 lacks the
prominent H bond contact with the catalytic oxyanion of S124, a
pivotal interaction conserved among all ligands co-crystallized
with Ag85 enzymes so far [8,9,20]. In effect 2 does not mediate
any of the three H bond contacts observed between the glucoside
of OTG and Ag85C in the co-crystal, even though the carboxylate
of 2 is within close 2.9 A ˚ distance to the W262.NHe of Ag85C.
3 extends the furthest into the hydrophilic sub-pocket, thereby
replacing water molecule 2025 (Fig. 3C), which is well coordinated
by the backbone amides of Q43, Y46 and G48 and the
carboxylate of D38. Since water 2025 is conserved in all of the
crystal structures of Ag85A, B and C, its replacement may be
energetically costly. Also the secondary amino group of 3 may be a
less preferred functionality in the hydrophobic sub-pocket, as
suggested by the SAR data from analogues of 5, where a tertiary
carbon to nitrogen substitution in this segment of the pocket led to
inactivity [22].
Although these 3D docking models have not been experimen-
tally validated by crystal structures and may be incorrect, three
common themes can be deduced. Firstly, the central pocket
segment is filled by diverse chemical matter. Secondly, the
occupancy of both terminal segments of the pocket varies. Thirdly,
the number of H bond contacts in the glucoside binding sub-
pocket as well as a few contacts in the hydrophobic sub-pocket
appear to be sub-optimal with respect to the interactions observed
with OTG.
Ligand efficiency benchmarking
The identification of diverse hit chemical matter and variant
ligand placement across the entire pocket is highly desirable for
synthetic library follow-up because chemical series with orthogonal
safety profiles can be pursued and hybrid design approaches are
enabled. However sub-optimal ligand - protein interactions are a
serious disadvantage, which may necessitate laborious subtractive
chemistry or even high-risk scaffold hopping. To explore the
protein interaction quality of 1 in more detail, we utilize the ligand
efficiency parameter, BEI, defined as –log10(Kd or IC50 or MIC
[mol/L])/(Mw [kDa]) [28]. Using its Kd value in the NMR
binding assay, an in vitro ligand binding efficiency, BEI, of 8.5 is
calculated for 1, which is substantially lower than the BEI of 20,
measured for the Ag85C ligand 5 in the same NMR-based Kd
assay [22]. Since marketed small molecule drugs for druggable
enzymes, such as protein kinase inhibitors, possess IC50-based BEI
values of 17 to 20 [29], substantial synthetic optimization of 1
seems mandatory.
With the goal of therapeutic usage, anti-mycobacterial ligand
efficiency is even more relevant. Calculated from its MIC against
MDR-Mtb, 1 possesses an anti-tubercular BEI of 9.9, which is in
line with the Msmeg MIC-based BEI of 9.0 of synthetic
phosphonate and sulfonate inhibitors of Ag85C, which were
designed to mimic the enzymatic transition state [30,31]. A similar
anti-mycobacterial BEI of 9.0 is calculated for the covalent Ag85C
inhibitor 6-azido-69-deoxytrehalose from its MIC against M.
aurum. However, compared with the fragment-derived analogue
of 5, 2-amino-6-propyl-cyclohexa[b]thiophene-3-carbonitrile (6),
with MIC-based BEI values of 17 to 18 against MDR-Mtb [22], 1
again underperforms. Benchmarking 1 against the most advanced
clinical phase anti-tuberculars, moxifloxacin (clinical phase III),
TMC207, PA-824 and OPC-67683 (all clinical phase II) with
MIC-based BEI values of 15, 13, 17 and 14 against Mtb strain
H37R, respectively, underlines the notion that 1 needs synthetic
optimization with respect to both ligand efficiency and absolute
potency towards a MIC of 0.5 mg/mL or lower [4,32,33].
In conclusion FRIGATE rapidly produced chemically diverse
hits for all parts of the catalytic pocket of Ag85C. One FRIGATE
hit, 1, was experimentally confirmed to bind to the catalytic site of
Ag85C and inhibits the growth of Msmeg and MDR-Mtb with a
robust MIC of 20 mg/mL. Although 1 does not match the in vitro
binding efficiency and Mtb growth inhibition efficiency of the
Ag85C ligand 6 and clinical development candidates blocking
other targets of Mtb, 1 is a good starting point for synthetic
optimization towards both improved target binding and anti-
tubercular potency. While most published virtual screens fail to
report hits with anti-bacterial activity [24,34,35,36], the discovery
of 1 shows that FRIGATE can quickly and cost-efficiently
generate hits with biological activity and is an attractive tool for
organizations that lack extensive compound screening infrastruc-
ture.
Methods
(see Text S1)
Supporting Information
Figure S1 Parameterization of the the SCG local
optimization algorithm. The average number of function
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28428and gradient evaluations needed for the SCG algorithm shows a
minimum at s=10
29 with a high quality convergence criterion of
eg=10
210, but not with a low quality eg=10
25. This finding holds
true for both the unbiased (left) and biased (right) training set.
(TIF)
Figure S2 The overlay of the 15N-HSQC spectra of
50 mM 15N-labeled Ag85C alone (blue) and Ag85C in the
presence of 400 mM 1 (red) and 550 mM OTG (green)
shows several CSPs common between 1 and OTG, such
as those labeled 12, 17, 19, 40 and 44 (arrows). The 15
reference resonances (labeled ‘r1’ to ‘r15’) remain virtually
unchanged.
(TIF)
Figure S3 The overlay of the
15N-HSQC spectra of
50 mM
15N-labeled Ag85C alone (blue) and Ag85C in the
presence of 400 mM 1 (red) and 400 mM 5 (green) shows
several CSPs common between 1 and 5, such as those
labeled 12, 17, 19, 40 and 44 (arrows). The 15 reference
resonances (labeled ‘r1’ to ‘r15’) remain virtually unchanged.
(TIF)
Figure S4 31 resolved CSPs (filled rhombs) and 15
reference resonances (open circles) from the
15N-HSQC
spectrum with OTG are plotted against the same CSPs
and reference resonances in the
15N-HSQC spectrum in
the presence of 1 or 2. (A) 20 out of the total 31 CSPs correlate
between 1 and OTG in showing mutual CSPs larger than the
variation of reference resonances. (B) 21 out of the total 31 CSPs
correlate between 1 and 5.( C) 27 out of the total 31 CSPs
correlate between 2 and OTG.
(TIF)
Figure S5 Chemical structures of 5 and 6.
(TIF)
Table S1 Ag85C binding and Msmeg antibacterial
activity of the selected 31 FRIGATE hits, sorted by
decreasing FRIGATE score from top to bottom.
(DOC)
Text S1 NMR binding site and antibacterial assay
results for the abovementioned compounds, experimen-
tal methods, description of computational algorithms.
(DOC)
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